Crosslink repair mechanisms are a double-edged sword in cancer therapy. On one hand, defects in these pathways can be exploited to sensitize cancer cells to certain drugs. For example, tumors with defective HR (due to BRCA mutations) are more susceptible to PARP inhibitors. On the other hand, enhanced repair capacity can confer resistance to crosslinking agents, posing a challenge in treatment.
